Close Menu

Atlas Ventures

The firms announced a deal to identify strategic investments in technology areas within agriculture "to support and complement Monsanto's interests and potential growth areas."

The startup has now raised a total of $26 million in Series A financing to support development of a biomarker-based cancer diagnostic.

The new preliminary prospectus offers for sale around 9.6 million shares by shareholders of the firm. Helicos won't receive any proceeds from the sale.

Short Reads: Feb 17, 2009

Premium

Life Technologies, Max Planck Institute for Evolutionary Anthropology, 454 Life Sciences, Applied Biosystems, Baylor College of Medicine, University of Bristol, University of Liverpool, John Innes Centre, Helicos BioSciences, Febit, and more…

Helicos filed the prospectus for 68.4 million shares held by investors who participated in a private placement in December. The firm would receive none of the proceeds from the sale of those shares, if any of them are sold.

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.